Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 629.20 | 554.05 | 488.13 | 509.80 | 360.13 |
Total Expenses | 561.66 | 517.99 | 406.35 | 426.46 | 331.29 |
Profit Before Tax | 67.54 | 36.07 | 81.78 | 83.34 | 28.28 |
Profit After Tax | 50.96 | 27.23 | 61.03 | 61.61 | 21.02 |
Operating Profit after Depreciation | 76.14 | 42.15 | 86.90 | 89.57 | 37.75 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 200.65 | 178.91 | 158.69 | 118 | 119.52 |
Total Non Current Assets | 289.22 | 250.63 | 196.01 | 162.43 | 148.85 |
Total Current Assets | 454.03 | 399.07 | 414.87 | 276.95 | 222.60 |
TOTAL ASSETS | 743.25 | 649.70 | 610.89 | 439.38 | 371.45 |
Total Shareholder's Fund | 491.25 | 439.25 | 426.17 | 245.03 | 189.68 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 43.26 | 34.02 | -33.48 | 59.95 | 31 |
Net Cash used in Investing Activities | -43.55 | -12.65 | -84.42 | -25.28 | -12.52 |
Net Cash used in Financing Activities | 0.99 | -19.84 | 122.82 | -34.57 | -18.06 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 354.17 | 289.18 | 212.55 | 233.25 | 181.28 |
Total Expenses | 309.65 | 252.27 | 196.38 | 200.54 | 165.55 |
Profit Before Tax | 44.52 | 36.92 | 16.16 | 32.71 | 15.73 |
Profit After Tax | 34.64 | 31.25 | 11.74 | 23.47 | 11.22 |
Operating Profit after Depreciation | 49.02 | 39.59 | 19.12 | 36.51 | 21.69 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 56.72 | 50.88 | 49.32 | 50.26 | 49.08 |
Total Non Current Assets | 323.17 | 315.54 | 312.81 | 212.84 | 212.86 |
Total Current Assets | 187.70 | 190.41 | 151.31 | 111.12 | 114.23 |
TOTAL ASSETS | 510.88 | 505.95 | 464.12 | 323.95 | 327.09 |
Total Shareholder's Fund | 416.87 | 395.59 | 378.72 | 246.85 | 229.67 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 34.96 | 16.87 | -37.80 | 48.77 | 9.97 |
Net Cash used in Investing Activities | -6.27 | 10.05 | -100.26 | -8.51 | 0.63 |
Net Cash used in Financing Activities | -24.08 | -26.13 | 137.99 | -40.14 | -10.60 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 151.56 | 139.44 | 186.08 | 158.92 | 152.59 |
Total Expenses | 136.83 | 121.28 | 164.39 | 135.33 | 129.76 |
Profit Before Tax | 9.65 | 14.74 | 25.18 | 20.51 | 18.25 |
Profit After Tax | 7.38 | 11.10 | 18.62 | 15.79 | 13.77 |
Operating Profit after Depreciation | 15.73 | 20.79 | 31.36 | 26.02 | 22.96 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 73.53 | 49.61 | 90.62 | 82.33 | 98.64 |
Total Expenses | 63.84 | 44.32 | 75.28 | 70.27 | 89.94 |
Profit Before Tax | 8.75 | 5.52 | 20.55 | 11.16 | 12.59 |
Profit After Tax | 6.60 | 4.25 | 15.31 | 8.51 | 10.66 |
Operating Profit after Depreciation | 10.81 | 7.41 | 23.49 | 13.35 | 14.49 |
₹3/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Kopran Ltd | ₹209.45 | ₹1,010.58 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
21 Jan 2025, 06:36 pm
06 Nov 2024, 02:37 pm
20 Aug 2024, 04:22 pm
31 Jul 2024, 12:21 pm
24 Jul 2024, 09:33 am